Standing department
The Ledger
The paperwork behind the category: which names return a US application record, what kinds of record the corpus holds for each compound, and how much of it cannot be published without qualified review.
Remit
The Ledger runs in every issue and holds the documentary position: the application register result for each name, the composition of the corpus by the kind of record it holds, and the portion of it that is written but withheld.
One warning belongs at the top of this department rather than in a footnote. The tier shown for a compound’s record composition is inferred from counts of study models and identity fields. It describes what this corpus holds. It is not an assessment of clinical efficacy, of safety, of study quality, or of scientific consensus about any compound, and it must not be read or quoted as one.
The commercial argument built on these tables is in the issue’s third feature.
Names returning a US application record
22 of 77 compound names return at least one application record; 55 return none. A count is a count of applications filed under that name over the register’s history, often across several sponsors and several forms. It is not a quality score, not a current marketing status, and not a statement about any product.
| Compound name as queried | Application records |
|---|---|
| Leuprolide | 21 |
| Desmopressin | 20 |
| Octreotide | 17 |
| Liraglutide | 11 |
| Vasopressin | 10 |
| Somatropin | 5 |
| Triptorelin | 4 |
| Oxytocin | 3 |
| Teriparatide | 3 |
| Exenatide | 2 |
| Tirzepatide | 2 |
| Afamelanotide | 1 |
| Bremelanotide | 1 |
| Dulaglutide | 1 |
| Elamipretide | 1 |
| Glutathione | 1 |
| Lixisenatide | 1 |
| Orforglipron | 1 |
| Pramlintide | 1 |
| Semaglutide | 1 |
| Setmelanotide | 1 |
| Tesamorelin | 1 |
What the corpus holds
The tier below is derived from counts of study models and identity fields. It is labelled inferred in the data and carries its own basis string. It describes which kinds of record this corpus holds for a compound. It is not an assessment of clinical efficacy, of safety, of study quality or of scientific consensus, and it must not be quoted as one.
| Tier, as the data labels it | Compounds |
|---|---|
| Animal and in vitro records only | 24 |
| Human trial records indexed | 23 |
| Limited human records | 16 |
| Preparation, protein or mixture | 13 |
| Study model not established | 1 |
Written and withheld
50 of the 77 profiles are classified as high impact, meaning the subject is one where a reader could mistake curated research for medical guidance. 50 of those are recorded as awaiting qualified human review, and the corresponding reference pages are built but withheld from indexing until a named qualified reviewer is recorded. The corpus as a whole carries 738 cited source records and 902 indexed study rows across 77 compounds in 11 classes.
Sources, and the queries that produced every figure above
- Drugs@FDA application register, queried through the openFDA drugsfda endpoint. U.S. Food and Drug Administration. Retrieved 2026-10-09. Read from this project’s own compound records, which store the result of a single automated query per compound name on the stated date together with the wording the query returned.https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:"<name>"&limit=5
- Peptide research corpus: 77 compound records and 77 evidence profiles. This project’s validated dataset, data/compounds and data/evidence. Counts are taken directly from the dataset files. A derived tier on an evidence profile is labelled INFERRED in the data and carries its own basis string, which is reproduced wherever a tier is printed.